Johnson & Johnson reported $97.9B of revenue over the trailing twelve months, +8.1% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $97.9B (to Q2 2026). Net income: $21.0B, trailing twelve months to Q2 2026. Free cash flow: $22.2B, trailing twelve months to Q2 2026. EPS: $8.62, trailing twelve months to Q2 2026.

JNJJohnson & Johnson

Healthcare

$261.45+53% 1Y

$261.45

$171.2152 weeks$278.28

JNJ as reported

Johnson & Johnson reported $97.9B of revenue over the trailing twelve months, +8.1% on the year before. 11 reported series are charted on this page, each one as filed.

$97.9B

Revenue, trailing twelve months · to Q2 2026 · +8.1% against the twelve months before

Net income: $21.0B
Net income · −7.2% year on year · trailing twelve months to Q2 2026
Free cash flow: $22.2B
Free cash flow · +20% year on year · trailing twelve months to Q2 2026
EPS: $8.62
EPS · −7.8% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for JNJ, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$97.9B	+8.1%	Q2 2026
Net income	$21.0B	−7.2%	Q2 2026
EPS	$8.62	−7.8%	Q2 2026
Gross margin	68%	n/a	Q2 2026
Operating margin	30%	n/a	Q1 2015 · 45 quarters behind
Net margin	21%	n/a	Q2 2026
ROE	29%	n/a	Q2 2026
ROA	12%	n/a	Q2 2026
ROIC	28%	n/a	Q1 2015 · 45 quarters behind
Free cash flow	$22.2B	+20%	Q2 2026
P/E	30.3	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.